Share-Based Compensation (Tables)

9 Months Ended

Mar. 31, 2016

Disclosure of Compensation Related Costs, Share-based Payments [Abstract]

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Options Outstanding

A summary of the stock option activity under the Company’s plans for the nine months ended March 31, 2016 is as follows:

	Number of shares			Weighted average exercise price
Options outstanding at June 30, 2015		12.5		$	23.49
Options granted		—		$	—
Less:
Options exercised		(4.1	)	$	21.39
Options canceled or expired		—		$	—
Options outstanding at March 31, 2016		8.4		$	24.51
Options exercisable at March 31, 2016		6.9		$	24.02

Schedule of Share-Based Compensation Arrangement by Share Based Payment Award Restricted Stock Units Outstanding

A summary of the RSU activity under the Company’s plans for the nine months ended March 31, 2016 is as follows:

	Number of shares			Weighted average grant date fair value
RSUs outstanding at June 30, 2015		1.0		$	37.63
RSUs granted		0.8		$	40.66
Less:
RSUs vested		(0.4	)	$	39.74
RSUs canceled		—		$	—
RSUs outstanding at March 31, 2016		1.4		$	38.78

Schedule of Share-Based Compensation Recognized in Consolidated Statements of Operations

Share-based compensation expense recognized and included in the condensed consolidated statements of income and comprehensive income was allocated as follows:

	Three months ended March 31,				Nine months ended March 31,
	2016		2015		2016		2015
Cost of molecular diagnostic testing	$	0.2	$	0.2	$	0.7	$	0.7
Cost of pharmaceutical and clinical services		0.1		0.1		0.3		0.4
Research and development expense		1.3		1.2		4.1		3.2
Selling, general, and administrative expense		6.0		11.0		18.8		27.3
Total share-based compensation expense	$	7.6	$	12.5	$	23.9	$	31.6